Arbutus Biopharma向Moderna(MRNA.US)提起與COVID槍擊病毒疫苗的專利侵權訴訟
格隆匯3月1日丨據路透,Arbutus Biopharma(ABUS.US)週一表示,因為Moderna(MRNA.US)侵犯其新冠病毒疫苗相關的美國專利,已對其提起訴訟,Arbutus表示,該公司開發了脂質納米顆粒(LNP),可以包裹信使RNA或mRNA基因材料,相關專利已授權給Geneant Sciences,該公司是Arbutus Biopharma和Roivant Sciences Ltd的合資企業。而Moderna否認這些指控,並將在法庭上對Genevant的指控進行有力的辯護。Moderna的COVID疫苗基於mRNA技術已獲准在70多個國家使用,其銷量一直在上升。該疫苗在2021年的銷售額為177億美元,預計到2022年將達到190億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.